Dianthus Therapeutics (DNTH) Financials

Dianthus Therapeutics logo
$86.98 -2.57 (-2.87%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$87.34 +0.36 (+0.41%)
As of 11/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Dianthus Therapeutics

Annual Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-9.74 -36 -58 -77 -75 -71 -28 -44 -85 -162
Consolidated Net Income / (Loss)
-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Net Income / (Loss) Continuing Operations
-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -163
Total Pre-Tax Income
-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -163
Total Operating Income
-9.27 -36 -60 -83 -79 -75 -30 -48 -102 -178
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 6.42 2.83 6.24 2.04
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 6.42 2.83 6.24 2.04
Operating Revenue
0.00 0.00 0.00 - - - 6.42 2.83 6.24 2.04
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
9.27 36 60 83 79 75 36 51 108 180
Selling, General & Admin Expense
3.49 7.83 19 24 28 28 6.74 18 25 34
Research & Development Expense
5.78 28 41 59 51 47 29 33 83 146
Total Other Income / (Expense), net
-0.16 0.24 2.45 6.20 3.77 3.56 1.23 4.62 17 16
Interest & Investment Income
0.00 0.24 2.45 6.20 3.77 3.56 1.15 4.76 17 16
Other Income / (Expense), net
- - - - - - 0.08 -0.15 -0.62 -1.03
Basic Earnings per Share
($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($32.57) ($8.45) ($2.55) ($4.20)
Weighted Average Basic Shares Outstanding
149.41K 1.86M 18.39M 37.01M 43.92M 54.95M 874.23K 5.15M 33.31M 38.62M
Diluted Earnings per Share
($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($32.57) ($8.45) ($2.55) ($4.20)
Weighted Average Diluted Shares Outstanding
149.41K 1.86M 18.39M 37.01M 43.92M 54.95M 874.23K 5.15M 33.31M 38.62M
Weighted Average Basic & Diluted Shares Outstanding
149.41K 1.86M 18.39M 37.01M 43.92M 58.80M 60.64M 29.35M 32.13M 44.47M
Cash Dividends to Common per Share
- - - - - - - $0.00 $0.00 $0.00

Quarterly Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-14 -18 -25 -28 -30 -32 -37 -64 -41 -50 -47
Consolidated Net Income / (Loss)
-14 -18 -25 -28 -30 -32 -37 -64 -41 -50 -47
Net Income / (Loss) Continuing Operations
-14 -18 -25 -28 -30 -32 -37 -65 -41 -50 -47
Total Pre-Tax Income
-14 -18 -25 -28 -30 -32 -37 -65 -41 -50 -47
Total Operating Income
-18 -22 -30 -32 -33 -35 -40 -70 -47 -61 -58
Total Gross Profit
0.87 1.86 2.17 1.33 1.16 0.00 0.00 0.87 0.00 0.76 1.21
Total Revenue
0.87 1.86 2.17 1.33 1.16 0.00 0.00 0.87 0.00 0.76 1.21
Operating Revenue
0.87 1.86 2.17 1.33 1.16 - 0.00 - - 0.76 1.21
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
19 24 32 33 34 35 41 70 47 62 60
Selling, General & Admin Expense
5.64 6.00 6.53 6.83 7.34 8.87 8.20 9.93 12 14 14
Research & Development Expense
13 18 26 26 27 26 32 60 35 49 46
Total Other Income / (Expense), net
4.10 4.60 4.73 3.48 3.67 3.30 3.52 5.11 5.70 11 12
Interest & Investment Income
4.22 4.71 4.45 3.99 3.79 3.40 3.66 5.27 6.27 12 12
Other Income / (Expense), net
-0.13 -0.11 0.28 -0.51 -0.13 -0.14 -0.14 -0.41 -0.26 -0.28 -0.31
Basic Earnings per Share
($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85) ($0.90) ($0.81)
Weighted Average Basic Shares Outstanding
25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M 56.03M 57.34M
Diluted Earnings per Share
($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85) ($0.90) ($0.81)
Weighted Average Diluted Shares Outstanding
25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M 56.03M 57.34M
Weighted Average Basic & Diluted Shares Outstanding
29.35M 29.35M 29.60M 32.13M 32.16M 32.19M 42.88M 44.47M 54.67M 55.93M 56.31M

Annual Cash Flow Statements for Dianthus Therapeutics

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
4.04 47 8.56 6.73 -6.92 73 7.79 117 -109 28
Net Cash From Operating Activities
-6.53 -22 -42 -57 -64 -60 -29 -37 -78 -129
Net Cash From Continuing Operating Activities
-6.53 -22 -42 -57 -64 -60 -29 -37 -78 -129
Net Income / (Loss) Continuing Operations
-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Consolidated Net Income / (Loss)
-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Depreciation Expense
0.01 0.38 0.88 1.84 1.98 2.02 0.03 0.07 0.10 0.11
Amortization Expense
0.00 0.00 -0.19 -1.01 0.18 - -0.49 -1.14 -5.70 -5.85
Non-Cash Adjustments To Reconcile Net Income
1.30 12 11 10 9.94 10 1.59 3.65 12 22
Changes in Operating Assets and Liabilities, net
1.60 1.32 4.17 8.83 -1.19 -1.53 -1.72 4.11 -0.02 17
Net Cash From Investing Activities
-0.14 -2.20 -92 1.53 -11 43 -60 20 -287 -123
Net Cash From Continuing Investing Activities
-0.14 -2.20 -92 1.53 -11 43 -60 20 -287 -123
Purchase of Property, Plant & Equipment
-0.14 -2.20 -7.67 -3.06 -0.40 -1.26 -0.14 -0.11 -0.11 -0.21
Purchase of Investments
0.00 0.00 -84 -144 -96 -45 -62 -57 -414 -435
Sale and/or Maturity of Investments
- 0.00 0.00 149 86 90 2.00 78 127 312
Net Cash From Financing Activities
11 71 142 62 68 90 97 134 256 280
Net Cash From Continuing Financing Activities
11 71 142 62 68 90 97 134 256 280
Issuance of Common Equity
0.00 0.00 93 61 65 87 - 0.00 25 273
Other Financing Activities, net
0.01 0.00 0.03 2.02 3.07 3.36 0.00 134 231 7.54
Cash Interest Paid
- - - - - - 0.00 0.00 0.00 0.00
Cash Income Taxes Paid
- - - - - - 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Dianthus Therapeutics

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
197 -16 -280 -11 -13 3.12 43 -4.90 577 -517 -55
Net Cash From Operating Activities
-15 -15 -21 -27 -28 -24 -31 -47 -29 -49 -50
Net Cash From Continuing Operating Activities
-15 -15 -21 -27 -28 -24 -31 -47 -29 -49 -50
Net Income / (Loss) Continuing Operations
-14 -18 -25 -28 -30 -32 -37 -64 -41 -50 -47
Consolidated Net Income / (Loss)
-14 -18 -25 -28 -30 -32 -37 -64 -41 -50 -47
Depreciation Expense
0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.04
Amortization Expense
-0.43 -0.33 -2.25 -2.69 -1.79 -1.03 -2.24 -0.79 -1.17 -5.58 -0.81
Non-Cash Adjustments To Reconcile Net Income
1.78 2.71 3.08 5.37 6.12 6.49 5.57 4.92 11 12 13
Changes in Operating Assets and Liabilities, net
-2.56 0.68 3.06 -1.72 -2.47 2.25 2.86 13 2.22 -5.01 -16
Net Cash From Investing Activities
-5.51 1.17 -259 -23 15 26 -201 37 -134 -479 -112
Net Cash From Continuing Investing Activities
-5.51 1.17 -259 -23 15 26 -201 37 -134 -479 -112
Purchase of Property, Plant & Equipment
-0.03 -0.02 -0.03 -0.03 -0.02 -0.05 -0.01 -0.14 -0.01 -0.18 -0.37
Purchase of Investments
-20 -6.81 -278 -108 -67 -33 -280 -55 -239 -566 -323
Sale and/or Maturity of Investments
15 8.00 19 85 82 60 79 92 105 87 212
Net Cash From Financing Activities
218 -2.20 0.30 40 0.16 0.57 275 4.88 739 10 107
Net Cash From Continuing Financing Activities
218 -2.20 0.30 40 0.16 0.57 275 4.88 739 10 107
Issuance of Common Equity
0.00 -2.24 - - 0.13 - 272 0.00 59 - 98
Other Financing Activities, net
230 0.05 0.30 0.48 0.03 0.57 2.06 4.88 2.94 10 9.16

Annual Balance Sheets for Dianthus Therapeutics

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
54 157 162 162 190 83 179 374 531
Total Current Assets
53 145 150 152 181 82 177 281 409
Cash & Equivalents
51 58 65 58 132 15 132 23 51
Short-Term Investments
0.00 84 81 91 45 60 41 252 353
Accounts Receivable
- - - - - 4.70 0.29 0.81 0.05
Prepaid Expenses
0.94 2.75 4.11 2.69 3.77 0.91 3.26 4.86 5.09
Plant, Property, & Equipment, net
1.96 10 9.89 8.31 7.46 0.14 0.19 0.19 0.30
Total Noncurrent Assets
0.00 1.78 1.78 1.78 1.78 0.94 1.77 93 121
Long-Term Investments
- - - - - - 0.00 82 110
Other Noncurrent Operating Assets
0.00 1.78 1.78 1.78 1.78 0.94 1.77 11 11
Total Liabilities & Shareholders' Equity
54 157 162 162 190 83 179 374 531
Total Liabilities
4.14 12 20 18 17 9.45 11 22 38
Total Current Liabilities
4.14 10 14 11 11 8.23 9.63 18 31
Accounts Payable
0.17 3.49 2.81 3.76 3.04 1.17 2.61 4.58 9.73
Accrued Expenses
3.98 6.93 11 7.67 7.82 6.61 6.50 13 19
Current Deferred Revenue
- - - - - 0.10 0.10 0.48 1.19
Other Current Liabilities
- - - - 0.00 0.35 0.42 0.32 0.37
Total Noncurrent Liabilities
0.00 1.25 6.21 6.28 6.40 1.23 0.90 3.08 6.79
Noncurrent Deferred Revenue
- 1.25 6.21 6.28 6.40 0.79 0.74 1.91 5.77
Other Noncurrent Operating Liabilities
0.00 - - - 0.00 0.44 0.17 1.17 1.02
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-42 146 141 144 173 -44 169 352 493
Total Preferred & Common Equity
-42 146 141 144 173 -44 169 352 493
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-42 146 141 144 173 -44 169 352 493
Common Stock
3.09 248 321 398 498 1.66 258 527 830
Retained Earnings
-45 -103 -179 -254 -326 -46 -89 -174 -337
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.01 0.01 -0.02 -0.03 -0.16 0.05 0.11 0.49

Quarterly Balance Sheets for Dianthus Therapeutics

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
79 192 382 369 354 349 326 577 1,247 1,213 1,276
Total Current Assets
79 191 381 366 287 271 264 414 1,120 898 856
Cash & Equivalents
63 157 330 314 34 10 13 56 628 111 56
Short-Term Investments
15 33 47 47 247 253 244 347 484 776 782
Accounts Receivable
- 0.75 0.44 0.84 1.39 1.00 0.04 5.00 1.23 0.11 0.58
Prepaid Expenses
1.05 0.83 3.01 3.31 3.68 6.77 6.18 6.21 7.42 11 18
Plant, Property, & Equipment, net
0.00 0.20 0.20 0.19 0.19 0.19 0.21 0.19 0.27 0.42 0.75
Total Noncurrent Assets
0.00 0.81 1.34 3.08 67 77 62 163 127 305 419
Long-Term Investments
- - - - 61 68 52 153 114 304 406
Other Noncurrent Operating Assets
0.00 0.81 1.34 3.08 5.09 9.08 11 11 13 1.22 13
Total Liabilities & Shareholders' Equity
79 192 382 369 354 349 326 577 1,247 1,213 1,276
Total Liabilities
4.03 14 9.78 11 16 20 23 31 46 41 35
Total Current Liabilities
4.03 13 8.96 10 16 17 20 24 38 34 29
Accounts Payable
0.81 1.37 2.61 3.70 7.57 8.27 5.40 6.71 5.27 6.39 5.50
Accrued Expenses
3.22 11 5.85 5.86 7.73 7.98 14 16 31 26 21
Current Deferred Revenue
- 0.10 0.10 0.10 0.10 0.48 0.48 0.95 1.49 1.52 1.59
Other Current Liabilities
0.00 0.41 0.40 0.38 0.31 0.23 0.21 0.22 0.40 0.37 0.35
Total Noncurrent Liabilities
0.00 1.00 0.82 0.71 0.64 3.02 2.90 7.14 7.29 6.86 6.31
Noncurrent Deferred Revenue
- 0.75 0.72 0.68 0.64 1.85 1.79 6.07 6.32 5.94 5.45
Other Noncurrent Operating Liabilities
0.00 0.26 0.10 0.03 0.00 1.17 1.12 1.07 0.97 0.91 0.86
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
75 178 373 358 338 329 303 546 1,201 1,172 1,241
Total Preferred & Common Equity
75 178 373 358 338 329 303 546 1,201 1,172 1,241
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
75 178 373 358 338 329 303 546 1,201 1,172 1,241
Common Stock
509 257 476 479 483 532 539 819 1,579 1,602 1,722
Retained Earnings
-434 -79 -103 -121 -146 -204 -236 -272 -378 -428 -474
Accumulated Other Comprehensive Income / (Loss)
-0.00 -0.00 -0.03 -0.04 0.68 0.27 0.10 0.16 -0.58 -2.13 -6.28

Annual Metrics And Ratios for Dianthus Therapeutics

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 33,151,539.00 38,989,517.00 48,304,981.00 58,777,271.00 - - - 42,876,015.00
DEI Adjusted Shares Outstanding
0.00 0.00 33,151,539.00 38,989,517.00 48,304,981.00 58,777,271.00 - - - 42,876,015.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -1.74 -1.97 -1.55 -1.21 - - - -3.79
Growth Metrics
- - - - - - - - - -
Profitability Metrics
- - - - - - - - - -
Net Operating Profit after Tax (NOPAT)
-6.49 -25 -42 -58 -55 -52 -21 -34 -71 -125
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -19.97% -20.23% -25.24%
Earnings before Interest and Taxes (EBIT)
-9.27 -36 -60 -83 -79 -75 -30 -48 -102 -179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.26 -35 -59 -82 -77 -73 -30 -49 -108 -185
Valuation Ratios
- - - - - - - - - -
Leverage & Solvency
- - - - - - - - - -
Liquidity Ratios
- - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -24 -46 -50 -55 -53 -23 -31 -72 -108
Efficiency Ratios
- - - - - - - - - -
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.00 -1.25 3.08 -4.54 -4.93 -4.25 -1.83 -4.85 -4.49 -21
Increase / (Decrease) in Invested Capital
0.00 -1.25 4.32 -7.61 -0.39 0.68 2.42 -3.01 0.36 -17
Book Value per Share
$0.00 ($22.68) $4.39 $3.62 $2.98 $2.94 ($50.75) $11.40 $11.91 $11.51
Tangible Book Value per Share
$0.00 ($22.68) $4.39 $3.62 $2.98 $2.94 ($50.75) $11.40 $11.91 $11.51
Total Capital
0.00 50 146 141 144 173 74 169 352 493
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -52 -143 -146 -149 -177 -75 -174 -357 -514
Capital Expenditures (CapEx)
0.14 2.20 7.66 3.06 0.40 1.26 0.14 0.11 0.11 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -3.21 -7.67 -10 -8.74 -7.10 -1.68 -5.90 -13 -26
Debt-free Net Working Capital (DFNWC)
0.00 48 135 136 140 170 74 168 262 379
Net Working Capital (NWC)
0.00 48 135 136 140 170 74 168 262 379
Net Nonoperating Expense (NNE)
2.94 10 16 19 20 19 7.68 9.83 14 38
Net Nonoperating Obligations (NNO)
0.00 -52 -143 -146 -149 -177 -75 -174 -357 -514
Total Depreciation and Amortization (D&A)
0.01 0.38 0.69 0.83 2.16 2.02 -0.46 -1.07 -5.61 -5.74
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($1.29) ($8.45) ($2.55) ($4.20)
Adjusted Weighted Average Basic Shares Outstanding
149.41K 1.86M 33.47M 39.33M 48.56M 54.95M 59.37M 5.15M 33.31M 38.62M
Adjusted Diluted Earnings per Share
($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($1.29) ($8.45) ($2.55) ($4.20)
Adjusted Weighted Average Diluted Shares Outstanding
149.41K 1.86M 33.47M 39.33M 48.56M 54.95M 59.37M 5.15M 33.31M 38.62M
Adjusted Basic & Diluted Earnings per Share
($65.15) ($19.12) ($3.13) ($2.07) ($1.71) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
149.41K 1.86M 18.39M 37.01M 43.92M 58.80M 60.64M 29.35M 32.13M 44.47M
Normalized Net Operating Profit after Tax (NOPAT)
-6.49 -25 -42 -58 -55 -52 -21 -34 -71 -125
Debt Service Ratios
- - - - - - - - - -
Payout Ratios
- - - - - - - - - -

Quarterly Metrics And Ratios for Dianthus Therapeutics

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 32,125,179.00 32,159,982.00 32,188,345.00 42,876,015.00 44,471,094.00 54,666,233.00 55,934,378.00
DEI Adjusted Shares Outstanding
- - - - 32,125,179.00 32,159,982.00 32,188,345.00 42,876,015.00 44,471,094.00 54,666,233.00 55,934,378.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - -0.92 -0.98 -1.14 -1.50 -0.92 -0.92 -0.83
Growth Metrics
- - - - - - - - - - -
Revenue Growth
83.61% 92.26% 135.06% 190.15% 33.07% -100.00% -100.00% - -100.00% 0.00% 0.00%
EBITDA Growth
-130.57% -89.32% -98.62% -161.25% -90.78% -59.39% -34.60% - -36.70% -86.63% -39.69%
EBIT Growth
-133.53% -88.68% -87.58% -149.33% -85.32% -57.13% -37.24% - -40.52% -76.13% -45.43%
NOPAT Growth
-132.25% -88.55% -89.73% -146.34% -85.93% -57.30% -34.74% - -40.26% -76.03% -45.14%
Net Income Growth
-93.93% -58.05% -70.52% -169.24% -114.66% -79.64% -46.04% - -38.37% -58.76% -26.87%
EPS Growth
93.33% 95.99% 80.42% -104.70% -51.85% -72.55% -31.08% - -3.66% -2.27% 16.49%
Operating Cash Flow Growth
-45.28% -207.08% -112.84% -131.52% -84.93% -64.45% -43.67% - -4.44% -105.01% -64.73%
Free Cash Flow Firm Growth
-45.09% -78.23% -6,154.62% -274.84% -119.82% -30.42% 13.84% - 52.55% 3.59% -99.24%
Invested Capital Growth
-41.75% 16.73% 59.03% 7.34% 32.58% -141.66% -91.91% - -712.18% -380.15% 73.50%
Revenue Q/Q Growth
91.25% 113.16% 16.59% -38.95% -12.29% -100.00% 0.00% - -100.00% 0.00% 59.00%
EBITDA Q/Q Growth
-36.86% -23.09% -40.74% -10.19% 0.06% -2.84% -18.85% - 32.20% -40.40% 11.51%
EBIT Q/Q Growth
-38.16% -24.18% -32.73% -9.49% -2.69% -5.29% -15.93% - 33.10% -31.97% 4.81%
NOPAT Q/Q Growth
-37.73% -24.43% -34.66% -6.74% -3.95% -5.27% -15.35% - 33.09% -32.13% 4.90%
Net Income Q/Q Growth
-30.15% -28.07% -42.98% -12.97% -3.77% -7.18% -16.24% - 36.62% -22.97% 7.11%
EPS Q/Q Growth
-103.34% 5.56% -45.10% -2.70% -7.89% -7.32% -10.23% - 44.44% -5.88% 10.00%
Operating Cash Flow Q/Q Growth
-26.04% 2.76% -46.39% -29.05% -0.68% 13.53% -27.89% - 38.58% -69.74% -2.76%
Free Cash Flow Firm Q/Q Growth
-85.13% -43.11% -72.74% 18.10% -8.56% 15.09% -14.11% - 63.62% -72.52% -135.83%
Invested Capital Q/Q Growth
10.29% 42.77% -89.11% 4.57% 34.73% -105.15% -50.17% - -13.24% -21.28% 91.71%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% - 0.00% 100.00% 100.00%
EBITDA Margin
-2,103.09% -1,214.49% -1,466.11% -2,646.23% -3,015.31% 0.00% 0.00% - 0.00% -8,844.15% -4,922.15%
Operating Margin
-2,041.65% -1,191.84% -1,376.61% -2,406.94% -2,852.71% 0.00% 0.00% - 0.00% -8,079.11% -4,832.40%
EBIT Margin
-2,056.06% -1,197.80% -1,363.67% -2,445.70% -2,863.46% 0.00% 0.00% - 0.00% -8,115.24% -4,858.35%
Profit (Net Income) Margin
-1,573.00% -945.09% -1,159.02% -2,144.80% -2,537.49% 0.00% 0.00% - 0.00% -6,598.55% -3,854.79%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.39% - 100.75% 100.00% 100.00%
Interest Burden Percent
76.51% 78.90% 84.99% 87.70% 88.62% 90.20% 91.00% - 86.61% 81.31% 79.34%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-22.31% -26.19% -25.99% -32.60% -28.73% -34.71% -28.57% - -22.70% -26.07% -22.61%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-28.46% -22.04% -26.77% -55.11% -51.11% 0.00% 0.00% - 0.00% -17.23% -14.91%
Return on Assets (ROA)
-21.77% -17.39% -22.75% -48.33% -45.29% 0.00% 0.00% - 0.00% -14.01% -11.83%
Return on Common Equity (ROCE)
-22.31% -26.19% -25.99% -32.60% -28.73% -34.71% -28.57% - -22.70% -26.07% -22.61%
Return on Equity Simple (ROE_SIMPLE)
-13.47% -15.82% -19.86% 0.00% -30.65% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-12 -16 -21 -22 -23 -24 -28 -49 -33 -43 -41
NOPAT Margin
-1,429.15% -834.29% -963.63% -1,684.86% -1,996.90% 0.00% 0.00% - 0.00% -5,655.37% -3,382.68%
Net Nonoperating Expense Percent (NNEP)
-0.55% -0.94% -1.59% -2.30% -1.77% -2.14% -1.91% - -1.06% -0.95% -0.64%
Return On Investment Capital (ROIC_SIMPLE)
- - - -6.34% -7.07% -8.07% -5.16% -9.87% -2.71% -3.67% -3.30%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
645.31% 321.90% 300.55% 515.01% 630.87% 0.00% 0.00% - 0.00% 1,781.47% 1,163.80%
R&D to Revenue
1,496.34% 969.94% 1,176.06% 1,991.93% 2,321.84% 0.00% 0.00% - 0.00% 6,397.63% 3,768.60%
Operating Expenses to Revenue
2,141.65% 1,291.84% 1,476.61% 2,506.94% 2,952.71% 0.00% 0.00% - 0.00% 8,179.11% 4,932.40%
Earnings before Interest and Taxes (EBIT)
-18 -22 -30 -32 -33 -35 -41 -70 -47 -62 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -23 -32 -35 -35 -36 -43 -71 -48 -67 -60
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.36 2.12 2.38 1.83 1.77 1.98 2.32 - 3.11 4.55 3.97
Price to Tangible Book Value (P/TBV)
2.36 2.12 2.38 1.83 1.77 1.98 2.32 - 3.11 4.55 3.97
Price to Revenue (P/Rev)
273.08 184.45 149.78 103.48 89.32 128.54 508.88 - 4,274.93 3,261.24 1,731.72
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
156.13 96.86 85.93 46.23 38.51 62.23 285.71 - 2,871.58 2,532.69 1,294.37
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-1.02 -1.01 -1.03 -1.02 -1.01 -1.01 -1.02 - -1.02 -1.02 -1.01
Leverage Ratio
1.04 1.03 1.06 1.06 1.04 1.05 1.05 - 1.04 1.04 1.04
Compound Leverage Factor
0.79 0.82 0.90 0.93 0.92 0.95 0.96 - 0.90 0.85 0.82
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
54.68 42.94 29.58 17.90 17.26 15.18 24.44 - 49.63 77.71 84.97
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
42.52 36.46 18.30 15.22 15.99 13.12 17.35 - 29.25 26.10 30.02
Quick Ratio
42.13 36.05 17.98 14.96 15.59 12.81 17.09 - 29.06 25.79 29.40
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-11 -16 -28 -23 -25 -21 -24 -32 -12 -20 -48
Operating Cash Flow to CapEx
-46,690.63% -85,458.82% -85,068.00% -88,529.03% -115,125.00% -51,939.13% -611,100.00% - -288,560.00% -27,061.33% -13,677.72%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.01 0.02 0.02 0.02 0.02 0.01 0.01 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 5.01 11.33 9.09 10.61 0.78 - 0.78 22.54 1.02
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 27.95 32.90 33.80 23.54 13.31 - 3.75 5.23 6.09
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 72.82 32.23 40.14 34.42 468.53 - 466.18 16.19 358.20
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 72.82 32.23 40.14 34.42 468.53 - 466.18 16.19 358.20
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-4.35 -2.49 -4.71 -4.49 -2.93 -6.02 -9.03 -21 -24 -29 -2.39
Invested Capital Turnover
-0.87 -1.50 -0.66 -1.34 -1.79 -1.10 -0.36 - -0.07 -0.09 -0.50
Increase / (Decrease) in Invested Capital
-1.28 0.50 6.78 0.36 1.42 -3.53 -4.33 -17 -21 -23 6.64
Enterprise Value (EV)
503 399 461 288 251 290 711 - 2,507 4,138 3,681
Market Capitalization
880 760 804 645 583 599 1,267 - 3,732 5,329 4,925
Book Value per Share
$12.70 $12.21 $11.51 $11.91 $10.23 $9.42 $16.98 $11.51 $27.01 $21.44 $22.19
Tangible Book Value per Share
$12.70 $12.21 $11.51 $11.91 $10.23 $9.42 $16.98 $11.51 $27.01 $21.44 $22.19
Total Capital
373 358 338 352 329 303 546 493 1,201 1,172 1,241
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-377 -361 -343 -357 -332 -309 -555 -514 -1,225 -1,190 -1,244
Capital Expenditures (CapEx)
0.03 0.02 0.03 0.03 0.02 0.05 0.01 0.14 0.01 0.18 0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5.07 -5.05 -9.34 -13 -9.18 -14 -13 -26 -30 -24 -10
Debt-free Net Working Capital (DFNWC)
372 356 272 262 254 244 390 379 1,082 863 828
Net Working Capital (NWC)
372 356 272 262 254 244 390 379 1,082 863 828
Net Nonoperating Expense (NNE)
1.26 2.06 4.24 6.10 6.29 7.18 8.56 16 8.26 7.18 5.71
Net Nonoperating Obligations (NNO)
-377 -361 -343 -357 -332 -309 -555 -514 -1,225 -1,201 -1,244
Total Depreciation and Amortization (D&A)
-0.41 -0.31 -2.23 -2.66 -1.77 -1.00 -2.21 -0.76 -1.14 -5.55 -0.77
Debt-free, Cash-free Net Working Capital to Revenue
-157.23% -122.61% -174.13% -205.12% -140.77% -297.73% -507.96% - -3,394.16% -1,448.29% -360.76%
Debt-free Net Working Capital to Revenue
11,537.44% 8,636.67% 5,064.83% 4,209.33% 3,894.02% 5,224.46% 15,667.74% - 123,897.82% 52,824.24% 29,097.15%
Net Working Capital to Revenue
11,537.44% 8,636.67% 5,064.83% 4,209.33% 3,894.02% 5,224.46% 15,667.74% - 123,897.82% 52,824.24% 29,097.15%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85) ($0.90) ($0.81)
Adjusted Weighted Average Basic Shares Outstanding
25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M 56.03M 57.34M
Adjusted Diluted Earnings per Share
($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85) ($0.90) ($0.81)
Adjusted Weighted Average Diluted Shares Outstanding
25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M 56.03M 57.34M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
29.35M 29.35M 29.60M 32.13M 32.16M 32.19M 42.88M 44.47M 54.67M 55.93M 56.31M
Normalized Net Operating Profit after Tax (NOPAT)
-12 -16 -21 -22 -23 -24 -28 -49 -33 -43 -41
Normalized NOPAT Margin
-1,429.15% -834.29% -963.63% -1,684.86% -1,996.90% 0.00% 0.00% - 0.00% -5,655.37% -3,382.68%
Pre Tax Income Margin
-1,573.00% -945.09% -1,159.02% -2,144.80% -2,537.49% 0.00% 0.00% - 0.00% -6,598.55% -3,854.79%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Dianthus Therapeutics remains well funded, but it continues to operate at a substantial loss. As of June 30, 2026, the company held $110.5 million in cash and $1.08 billion in short- and long-term investments, providing approximately $1.19 billion of liquid resources. Total liabilities were only $41.2 million versus $1.17 billion of equity, indicating a relatively strong balance sheet despite ongoing operating losses.

However, the company’s cash burn has accelerated. Net cash used in operating activities increased to $49.0 million in Q2 2026 from $28.9 million in Q1 and $30.6 million in Q3 2025. Dianthus reported a $50.2 million net loss in Q2, compared with losses of $40.8 million in Q1 2026 and $36.8 million in Q3 2025. Research and development spending has also risen sharply, reaching $48.7 million in Q2 from $34.5 million in Q1 and $25.5 million in Q2 2024.

  • Large liquidity position: Cash, short-term investments and long-term investments totaled approximately $1.19 billion at the end of Q2 2026, giving Dianthus significant financial resources to fund its clinical programs.
  • Limited balance-sheet leverage: Total liabilities were approximately $41.2 million, or roughly 3% of total assets. This reduces near-term solvency risk compared with highly leveraged development-stage biotechnology companies.
  • Interest income is providing support: Interest and investment income increased to $11.5 million in Q2 2026 from $6.3 million in Q1 and $5.3 million in Q4 2025, partially offsetting operating losses.
  • Revenue has begun to appear: Q2 2026 revenue was $761,000 after no reported revenue in Q1 2026. Although still modest, revenue could become more meaningful if collaboration or product-related payments increase.
  • Investment portfolio changes are distorting quarterly cash flow: Dianthus purchased $565.8 million of investments and received $87.4 million from investment maturities or sales in Q2. The resulting $478.5 million investing cash outflow largely reflects portfolio allocation rather than operating deterioration.
  • Potential funding runway remains substantial but uncertain: Using Q2 operating cash usage of $49.0 million as a simple quarterly benchmark, the company’s liquid resources could support more than five quarters of operations. Actual runway will depend on clinical spending, investment returns and future financing activity.
  • Operating losses remain persistent: Dianthus has reported losses in every recent quarter, with the Q2 2026 net loss reaching $50.2 million. The company has not demonstrated sustainable profitability.
  • Operating cash burn is worsening: Cash used in operations rose about 70% sequentially from $28.9 million in Q1 2026 to $49.0 million in Q2. This increases the pace at which the company must deploy its capital.
  • Research spending is escalating: Q2 research and development expense of $48.7 million was approximately 41% higher than in Q1 and nearly double the $26.3 million reported in Q4 2024. Higher spending may support pipeline development, but it also raises execution and funding risks.
  • Shareholder dilution has increased: Weighted-average basic shares outstanding rose to 56.0 million in Q2 2026 from 48.0 million in Q1 and 38.6 million in Q4 2025. The Q1 cash-flow statement also recorded $58.9 million of common-equity issuance, reducing each existing shareholder’s percentage ownership.

For investors, the main financial tradeoff is clear: Dianthus has built a sizable capital base and carries little reported liability, but it is consuming cash faster as development spending expands. The company’s investment portfolio may provide several quarters of funding, yet the long-term outlook will depend on clinical progress, future revenue generation and whether additional equity financing is required.

11/18/26 03:04 AM ETAI Generated. May Contain Errors.

Dianthus Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dianthus Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Dianthus Therapeutics' net income appears to be on a downward trend, with a most recent value of -$162.34 million in 2025, falling from -$9.43 million in 2016. The previous period was -$84.97 million in 2024. View Dianthus Therapeutics' forecast to see where analysts expect Dianthus Therapeutics to go next.

Dianthus Therapeutics' total operating income in 2025 was -$177.93 million, based on the following breakdown:
  • Total Gross Profit: $2.04 million
  • Total Operating Expenses: $179.97 million

Over the last 9 years, Dianthus Therapeutics' total revenue changed from $0.00 in 2016 to $2.04 million in 2025, a change of 203,600,000.0%.

In the past 13 quarters, Dianthus Therapeutics' cash and equivalents has ranged from $10.12 million in Q1 2025 to $627.67 million in Q1 2026, and is currently $55.69 million as of their latest financial filing in Q3 2026.

Dianthus Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2016.

Over the last 9 years, Dianthus Therapeutics' book value per share changed from 0.00 in 2016 to 11.51 in 2025, a change of 1,150.8%.



Financial statements for NASDAQ:DNTH last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners